Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.63 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.47 |
| ▸ | TERT | O14746 | 2/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790187 | 1.00 | HCAR2 (0.63) | HCAR2GPR88MEN1CASP3KMT2A | |
| SCHEMBL6790198 | 1.00 | HCAR2 (0.63) | HCAR2GPR88MEN1CASP3KMT2A | |
| SCHEMBL6782484 | 0.87 | KDM4E (0.57) | HCAR2KMT2AKDM4ELTB4R | |
| SCHEMBL6782488 | 0.87 | KDM4E (0.57) | HCAR2KMT2AKDM4ELTB4R | |
| SCHEMBL6782491 | 0.87 | KDM4E (0.57) | HCAR2KMT2AKDM4ELTB4R | |
| SCHEMBL15396459 | 0.84 | LTB4R (0.47) | HCAR2DEGS1LTB4RROCK2HDAC4 | |
| SCHEMBL15396769 | 0.83 | SMN1; SMN2 (0.63) | HCAR2MEN1KMT2AKDM4EDEGS1 | |
| SCHEMBL15396770 | 0.83 | NPC1 (0.54) | HCAR2DEGS1LTB4R | |
| SCHEMBL2950480 | 0.81 | LTB4R (0.61) | MEN1KMT2AKDM4ELTB4R | |
| SCHEMBL9607120 | 0.81 | HDAC4 (0.48) | HCAR2DEGS1LTB4RHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727250-B2 | ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-04-27 | — | — | US | disclosed |
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-07-25 | — | — | US | disclosed |
| US-6362210-B1 | ANTITUMOR, ANTICANCER AGENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | TERT, NAT1, POT1 | HCAR2 1203/4885GPR88 2890/4885MEN1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.